Navigation Links
AMRI Announces First Quarter 2013 Results and Raises EPS Guidance for the Year
Date:5/7/2013

act revenue$
46,493$
42,710Recurring royalties12,91310,985Total revenue59,40653,695Cost of contract revenue37,82239,670Technology incentive award1,1141,099Research and development105373Selling, general and administrative9,5499,846Restructuring charges879688Impairment charges5343,967Total operating expenses50,00355,643Income (loss) from operations9,403(1,948)Interest expense, net(82)(142)Other  income (expense), net452(792)Income (loss) before income taxes 9,773(2,882)Income tax expense 3,268925Net income (loss) $
,505$
(3,807)Basic and diluted income (loss) per share$
.21$
(0.13)Albany Molecular Research, Inc.Selected Consolidated Balance Sheet Data (unaudited)(Dollars in thousands)March 31,2013December 31, 2012Cash and cash equivalents$
28,535

$
23,293Restricted cash1,032

702Accounts receivable, net36,345

42,496Royalty income receivable12,978

8,180Inventory32,763

28,216Total current assets124,580

113,424Restricted cash4,345

4,524Property and equipment, net132,875

135,519Total assets269,997

262,862Total current liabilities36,557

35,986Long‑term debt, excluding current installments7,048

7,227Total liabilities56,421

56,721Total stockholders' equity213,576

206,141Total liabilities and stockholders' equity269,997

262,862 

Table 1:  Reconciliation of first quarter 2013 and 2012 reported income (loss) from operations, net income (loss) and earnings (loss) per diluted share to adjusted income from operations, adjusted net income and adjusted earnings per share:(Dollars in thousands, except for per share data)First Quarter
2013First Quarter
2012Income (loss) from operations, as reported$
9,403$
(1,948)Impairment charges5343,967Restructuring charges879688Income from operations, as adjusted$
,816$
2,707Net income (loss), as reported$
,505$
(3,807)Adjustments, net of tax:Im
'/>"/>

SOURCE AMRI
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Rigel Announces First Quarter 2013 Financial Results
2. Mindray Announces First Quarter 2013 Financial Results
3. Lilly Announces CEO Dr. John Lechleiter to Undergo Scheduled Surgery
4. Hologic Announces Second Quarter Fiscal 2013 Operating Results
5. Array Announces Global Phase 3 Trial Evaluating MEK162 In Patients With Low-Grade Serous Ovarian Cancer
6. AG Mednet Announces Partnership with The Methodist DeBakey Heart & Vascular Center Echocardiography Core Lab
7. Isis Pharmaceuticals Announces the Initiation of a Clinical Study of ISIS-STAT3 Rx in Patients with Liver Cancer
8. Apollo Medical Holdings Announces Record Fiscal Year-End Results
9. Atrium Medical Announces 1-year results of the INFUSE-AMI Trial
10. Premier Home Medical Supply Vendor Med Supply Shop Announces Drive Spring Promotion
11. Volcano Announces First Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... 2015 Research and Markets ... the "Surgical/Operating Microscopes Market by Application & ... report to their offering.      (Logo: ... is poised to reach $806.6 million by 2020 ... of 12.3% from 2015 to 2020. , ,Major ...
(Date:5/29/2015)... British Columbia and MENLO ... -- DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ... on developing and commercializing proven cancer therapies in ... at the American Association of Cancer Research ... on the potential for its lead product candidate ...
(Date:5/29/2015)... 2015 Amgen (NASDAQ: AMGN ) ... 3, global, randomized, placebo-controlled trials evaluating AMG 416, ... hyperparathyroidism (SHPT) in patients with chronic kidney disease ... endpoint, demonstrating that a greater proportion of patients ... than 30 percent reduction in parathyroid hormone (PTH) ...
Breaking Medicine Technology:Surgical/Operating Microscopes Market by Application & End User - Global Forecast to 2020 for the $806 Million Industry 2DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 2DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 3DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 4DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 5Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 2Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 3Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 4Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 5Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 6Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 7
(Date:5/30/2015)... (PRWEB) May 30, 2015 San ... that she is offering a free analysis and consultation ... offer coincides with Disability Awareness Month, which was created ... members across the United States such as Polk recognize ... raise awareness about the possibility of disability, as well ...
(Date:5/30/2015)... Miami, FL (PRWEB) May 30, 2015 ... (NLHEP) partners with Pulmonary Horizons to offer one ... to effectively identify and discuss successful practices to diagnose, ... of Attending the Pulmonary Horizons Conference is ... that can address the Overall Needs of Patients with ...
(Date:5/30/2015)... Las Vegas, Nevada (PRWEB) May 30, 2015 ... effective treatment of acne scars, large pores, deep wrinkles, ... by a licensed medical professional, such as Dr. F. ... conducted some of the clinical trials in Las Vegas. ... and SmartScan technology into a system that delivers proven ...
(Date:5/29/2015)... Montclair, NJ (PRWEB) May 30, 2015 ... and ever changing local and federal regulations, we ... needs of their patients who are suffering from ... regulations,” says Srinivas Nalamachu, MD, professor of rehabilitation ... Research Institute in Overland Park, Kansas. , A ...
(Date:5/29/2015)... May 29, 2015 What does community ... Denver Foundation, community comes together to plant gardens, to ... neighborhoods and awareness of critical issues. Community invites everyone ... and beyond. , "What Community Does" was commissioned by ... in Colorado, and released during the foundation’s Annual Celebration ...
Breaking Medicine News(10 mins):Health News:San Luis Obispo Insurance Agent Susan Polk Offering Complementary Insurance Analysis In Honor Of Disability Awareness Month 2Health News:Pulmonary Horizons 2nd Annual COPD Conference Miami Hilton Downtown, July 17-19, 2015 Patient Centered Cross-Continuum Education to Improve the Care of Patients with COPD 2Health News:Pulmonary Horizons 2nd Annual COPD Conference Miami Hilton Downtown, July 17-19, 2015 Patient Centered Cross-Continuum Education to Improve the Care of Patients with COPD 3Health News:Announcing Ground-Breaking Technology for Anti-Aging, FDA Approved, Venus Viva. 2Health News:Announcing Ground-Breaking Technology for Anti-Aging, FDA Approved, Venus Viva. 3Health News:PAINWeekEnd Kansas City: Pain Management CME for the Main Street Practitioner 2Health News:What Community Does: A New Video from The Denver Foundation 2
... Pharmaceuticals, Inc. (OTC Bulletin Board: TDLP) a specialty pharmaceutical ... that they anticipate reporting top-line results from their current ... of 2009. , , The Phase ... trial to evaluate the efficacy and safety of Ketotransdel, ...
... High Resolution Monitoring of Drug Efficacy and Safety ... Based on its recent analysis in the ... & Sullivan recognizes Singulex, Inc. with the 2009 ... Innovation for pioneering the Erenna Immunoassay System. This ...
... NTY ) ( www.NBTY.com ), a leading global manufacturer and marketer of nutritional supplements, today announced the ... unaudited net sales results for May 2009 by segment are as follows: , , , ... NET SALES, ... (Preliminary and Unaudited), ...
... -- As the slumping economy continues to ... streamlining costs and creating additional efficiencies while continuing to ... those in need for charity care or self-pay discounts. ... landscape, TransUnion announced today new enhancements to its patented ...
... ... seniors nationwide. , ... (Vocus) June 15, 2009 -- VaxAmerica, a program of FFF Enterprises, Inc., ... into a partnership with Emeritus Senior Living. The alliance will encourage the 26,500 seniors ...
... ... have developed the strongest and most effective libido/intimacy enhancement therapy called VaietTM 110/L-Arginine for ... ... to announce the release of their exclusive Viagra/Arginine Intimacy Enhancement Therapy or VAIET (named ...
Cached Medicine News:Health News:Transdel Pharmaceuticals Provides Update on Timing of Results for Phase 3 Study 2Health News:Transdel Pharmaceuticals Provides Update on Timing of Results for Phase 3 Study 3Health News:Frost & Sullivan Recognizes Singulex for Erenna(R) Immunoassay System 2Health News:Frost & Sullivan Recognizes Singulex for Erenna(R) Immunoassay System 3Health News:Frost & Sullivan Recognizes Singulex for Erenna(R) Immunoassay System 4Health News:NBTY Announces Preliminary Unaudited Net Sales Results for May 2009 2Health News:NBTY Announces Preliminary Unaudited Net Sales Results for May 2009 3Health News:NBTY Announces Preliminary Unaudited Net Sales Results for May 2009 4Health News:TransUnion Revenue Manager(SM) Meets Healthcare Challenges Brought On By Today's Economy with New Features 2Health News:TransUnion Revenue Manager(SM) Meets Healthcare Challenges Brought On By Today's Economy with New Features 3Health News:VaxAmerica Enters Partnership with Emeritus Senior Living 2Health News:VaxAmerica Enters Partnership with Emeritus Senior Living 3Health News:After 10 Years A Stronger and More Enhanced Form of Viagra Now Available 2Health News:After 10 Years A Stronger and More Enhanced Form of Viagra Now Available 3Health News:After 10 Years A Stronger and More Enhanced Form of Viagra Now Available 4
Shielding's new Surgical Drop Away / Flex Back Apron offers top of the shoulder velcro flaps for an adjustable fit. Features elastic back panels for added comfort and support. For quick removal apron...
Shielding's Standard Coat Apron with open back allows for freedom of movement, maximum flexibility and increased comfort....
This set includes 2 small, 1 medium, 1 large gonad shields and a belt. The shields and belt is an interchangeable system attached by velcro....
Lap pad used to protect pelvic regions...
Medicine Products: